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Strong evidence suggests that rare mutations of severe effect are responsible for a substantial 
portion of complex human disease. Evolutionary forces generate vast genetic heterogeneity 
in human illness by introducing many new variants in each generation. Current sequencing 
technologies offer the possibility of finding rare disease-causing mutations and the genes that 
harbor them.“Every unhappy family is unhappy in its 
own way,” wrote Tolstoy in Anna Kar-
enina. Tolstoy was reflecting on the indi-
vidually unique nature of human tragedy. 
We suggest that this principle also cap-
tures the misfortune of human disease. 
That is, from the perspective of genetics, 
we suggest that complex human disease 
is in fact a large collection of individually 
rare, even private, conditions. Disentan-
gling the paradoxes embedded in this 
idea will be the subject of this Essay.
In molecular terms, we suggest 
that human disease is characterized 
by marked genetic heterogeneity, far 
greater than previously appreciated. 
Converging evidence for a wide range 
of common diseases indicates that 
heterogeneity is important at multiple 
levels of causation: (1) individually rare 
mutations collectively play a substantial 
role in causing complex illnesses; (2) 
the same gene may harbor many (hun-
dreds or even thousands) different rare 
severe mutations in unrelated affected 
individuals; (3) the same mutation may 
lead to different clinical manifestations 
(phenotypes) in different individuals; 
and (4) mutations in different genes in 
the same or related pathways may lead 
to the same disorder.
This degree of allelic, locus, and 
phenotypic heterogeneity has impor-
tant implications for gene discovery. In 
particular, causality in this context can 
almost never be resolved by large-scale 
association or case-control studies. This 
degree of heterogeneity also has impor-
tant implications for development of 
molecular treatments and their appropri-
ate use by individual patients.210 Cell 141, April 16, 2010 ©2010 Elsevier InAn Evolutionary Perspective
The genetic bases of disease in mod-
ern humans reflect the architecture and 
evolution of the human genome. The old-
est human alleles originated in Africa, in 
parallel with the development of our spe-
cies, millions of years before people first 
migrated out of Africa 50,000 to 60,000 
years ago (Cavalli-Sforza et al., 1994; 
Cavalli-Sforza and Feldman, 2003) (Fig-
ure 1A). These ancient polymorphisms 
are shared by all human populations 
and account for approximately 90% of 
human variation. These polymorphisms 
provided the single-nucleotide polymor-
phisms (SNPs) of the HapMap (Tishkoff 
and Verrelli, 2003; The International Hap-
Map Consortium, 2007).
Yet new alleles constantly arise, at 
an estimated rate of approximately 175 
per diploid human genome per genera-
tion (Nachman and Crowell, 2000) (Fig-
ure 1B). Exponential population growth, 
fueled by the development of agriculture 
in the past 10,000 years and of urbaniza-
tion in the past 700 years, has resulted 
in a vast number of new alleles. Col-
lectively, these alleles have generated 
an immense degree of genetic varia-
tion. Given the size of the present day 
human population, every point mutation 
compatible with life is likely present in 
someone, somewhere. Many of these 
rare alleles are found in only one person 
or family. Thus the paradox: most human 
variation is ancient and shared, but most 
alleles are recent and rare.
Whole-genome sequencing efforts 
have revealed millions of previously 
unreported variants in healthy individu-
als, including single base pair substitu-c.tions, small insertions and deletions, 
and larger copy number mutations 
(McKernan et al., 2009). Most of these 
mutations likely have no functional sig-
nificance and persist by chance in the 
absence of selective pressure. In con-
trast, mutations with deleterious effects, 
either on viability before reproduction or 
on fertility, are less frequently transmit-
ted to subsequent generations. By this 
reasoning, it should be no surprise that 
severe mutations associated with early-
onset disease are disproportionately of 
recent origin and are therefore individu-
ally very rare.
Common Disease—Many Rare 
Alleles
Rare large-effect mutations are now 
recognized as causes of many different 
common medical conditions. A thorough 
review of the rare variant literature for 
human disease is well beyond the scope 
of this commentary. Here we briefly con-
sider a few very different complex disor-
ders for which rare mutations have been 
implicated, drawing in part from our own 
research.
Inherited Predisposition to Breast 
Cancer
Rare severe alleles have been impli-
cated in all forms of inherited suscep-
tibility to cancer. Inherited predispo-
sition to breast cancer is associated 
with germline mutations in at least 
13 genes (Walsh and King, 2007) 
(Figure 2A). Thousands of different 
loss-of-function mutations have been 
detected in BRCA1 and BRCA2 (Fig-
ure 2B); all of these mutations are indi-
vidually rare, and each independently 
Figure 1. Human Migrations and Genetic Diversity
(A) The oldest human alleles originated in Africa well before the diasporas of modern humans 
50,000–60,000 years ago. These oldest alleles are common in all populations worldwide. Approximately 
90% of the variability in allele frequencies is of this sort. (Figure adapted from Cavalli-Sforza and Feld-
man, 2003.) 
(B) Origins of common and rare alleles. KYA refers to “thousand years ago.” Horizontal arrows sug-
gest continuing cross-migration between continental populations. Development of agriculture in the past 
10,000 years and of urbanization and industrialization in the past 700 years has led to rapid populations 
growth and therefore to the appearance of vast numbers of new alleles, each individually rare and spe-
cific to one population or even to one family. (Figure adapted from Tishkoff and Verrelli, 2003.)confers very high risks for breast and 
ovarian cancers. Rare germline muta-
tions in p53, PTEN, CHEK2, PALB2, 
ATM, BRIP1, CDH1, and STK1 are 
also associated with increased risk 
of breast cancer, ranging from 2-fold 
for CHEK2 to 10-fold for p53. Each 
of these genes operates in networks 
integral to DNA repair and genomic 
integrity. For each gene, the combina-
tion of inherited and somatic loss-of-
function mutations (“2 hits”) leads to 
errors of DNA repair and ultimately to 
tumor development. In addition, bial-
lelic germline loss-of-function muta-
tions in BRCA2, BRIP1, and PALB2 cause various forms of Fanconi Ane-
mia, all of which are characterized by 
genomic instability and early-onset 
cancers.
Genetic heterogeneity of inherited 
predisposition to breast cancer serves 
as a model for other complex illnesses. 
The disorder results from any one of 
thousands of different mutations in any 
one of multiple different genes, but all 
the implicated genes encode proteins 
in related pathways (Walsh and King, 
2007). We suggest that the degree of 
biological complexity underlying a phe-
notype is an excellent predictor of locus 
heterogeneity. We further suggest that Cell age at onset and severity of the illness 
are excellent predictors of allelic het-
erogeneity at each locus.
Inherited Hearing Loss
Dozens of genes harbor inherited muta-
tions leading to nonsyndromic hearing 
loss, and each gene harbors multiple 
pathogenic mutations (Dror and Avraham, 
2009). Depending on the gene and muta-
tion, inheritance of the hearing loss may 
be dominant or recessive and autosomal, 
X-linked, or mitochondrial. All deafness-
causing mutations are recent and all but 
one are individually rare. The one frequent 
mutation, 30 delG in connexin 26, is the 
exception that proves the rule: it is not 
a common shared ancestral variant but 
rather has occurred independently mul-
tiple times in a mutational hotspot. Genes 
responsible for hearing loss encode pro-
teins involved in a wide variety of bio-
logical processes in the inner ear, includ-
ing development and maintenance of 
cytoskeletal structures, myosin motors, 
gap junction transport and signaling, ion 
channels, and transcriptional regulators 
(Figure 3). Mutations in microRNA have 
also been identified in hearing loss. The 
theme is the same as for inherited predis-
position to cancer: any one of many dif-
ferent mutations in any one of many dif-
ferent genes lead to related phenotypes.
Genetics of Lipid Metabolism
Individually rare variants in genes related 
to lipid metabolism are associated with 
extreme levels of high-density lipopro-
tein cholesterol (HDL-C) (Cohen et al., 
2004) and low-density lipoprotein cho-
lesterol (LDL-C) (Cohen et al., 2006). 
Although each variant only explains 
a small number of cases, collectively 
these mutations are responsible for a 
substantial portion of metabolic dis-
ease. The design for identifying these 
alleles was ingenious: candidate genes, 
defined as those causing rare recessive 
metabolic disorders, were sequenced 
in genomic DNA of individuals without 
overt disease but with extreme values of 
the trait of interest, i.e., levels of HDL or 
LDL cholesterol. This proved a power-
ful and efficient strategy for discovering 
causal variants associated with complex 
genetic traits (Fahmi et al., 2008).
Genetics of Severe Mental Illness
Emerging research suggests that rare 
mutations play important roles in neu-
ropsychiatric disorders, including autism 141, April 16, 2010 ©2010 Elsevier Inc. 211
and schizophrenia (Figure 4). A sub-
stantial portion of autism appears to be 
caused by rare point mutations, dele-
tions, duplications, and larger chromo-
somal abnormalities (Bucan et al., 2009). 
Autism is characterized by rare structural 
mutations, including a disproportion-
ately high rate of de novo large (>100 kb) 
deletions and duplications (Sebat et al., 
2007). Large structural mutations that 
reoccur independently multiple times in 
genomic “hotspots,” including on chro-
mosomes 1q21.1, 15q11-q13, 16p11.2, 
and 22q11.21, may each explain small 
subsets of cases (Bucan et al., 2009). 
Copy number mutations in patients 
with autism may disproportionally dis-
rupt genes involved with neuronal cell-
adhesion or ubiquitin degradation, both 
important networks for brain develop-
ment (Glessner et al., 2009). In addition, 
rare severe mutations in multiple genes 
important for brain development, includ-
ing NRXN1, CNTN4, CNTNAP2, NLGN4, 
DPP10, and SHANK3, have been iden-
tified in patients with autism spectrum 
disorders (Guilmatre et al., 2009).
Similar results have been observed for 
schizophrenia. We found that compared 
to healthy controls, individuals with 
schizophrenia were 3-fold more likely 
to harbor rare structural genomic muta-
tions that impacted genes (Walsh et al., 
2008). The risk was even higher in sub-
jects with early onset of schizophrenia. 
Each rare mutation disrupted a different 
gene or genes. However, the disrupted 
genes were not a random sample of the 
genome. Genes disrupted in patients 
were disproportionally involved with 
signaling and neurodevelopment (e.g., 
neuregulin and glutamate pathways), 
whereas genes disrupted in controls 
did not cluster in any particular path-
ways. Several independent studies have 
replicated and extended our findings. 
Compared to controls, individuals with 
schizophrenia carried significantly more 
de novo structural mutations (Xu et al., 
2008) and more structural mutations at 
genomic hotspots, including chromo-
somes 1q21.1, 15q13.3, 16p13.1, and 
22q11.2 (Stefansson et al., 2008; Interna-
tional Schizophrenia Consortium, 2008).
These results suggest that a substan-
tial portion of autism and schizophrenia 
is caused by individually rare mutations—
small and large—that disrupt the function 212 Cell 141, April 16, 2010 ©2010 Elsevier InFigure 2. Genetic Heterogeneity of Inherited Predisposition to Breast Cancer
(A) Thus far, 13 genes have been identified that harbor loss-of-function mutations responsible for in-
herited susceptibility to human breast cancer. Each susceptible woman carries an inherited mutation in 
only one (or very occasionally, two) of these genes. BRCA1 and BRCA2 are the most frequently altered 
of these genes. Inherited mutations in TP53 and PTEN are fortunately very rare and lead to young onset 
breast cancer in the context of Li-Fraumeni syndrome and Cowden disease, respectively. Most of the 
genes illustrated encode proteins critical to the maintenance of genomic integrity. The large number of 
high-incidence breast cancer families with no mutations in any of these genes suggests that additional 
genes remain to be found. 
(B) At BRCA1, more than 1000 different alleles increase susceptibility to breast and ovarian cancers. The 
figure shows positions of frameshift and nonsense mutations along the BRCA1 gene, which is in blue, 
with exons indicated. Among mutation carriers, cancer development is caused by the combination of the 
inherited mutation and a subsequent somatic mutation, leading to complete loss of BRCA1 function in 
the affected tissue.of genes operating in critical neurode-
velopmental pathways. Several genomic 
hotspots have been implicated in more 
than one psychiatric or neurocognitive 
phenotype (Cook and Scherer, 2008). The 
converse is also true: the same mutation 
may be associated with different psychi-
atric disorders or with no illness at all. 
For example, in the Scottish kindred har-
boring a chromosomal translocation dis-
rupting DISC1, 29 translocation carriers 
presented variously with schizophrenia, 
bipolar disorder, major depressive dis-
order, or no mental illness (Chubb et al., 
2008). Similarly, there are several genes, c.including NRXN1, PRODH, DOC2A, and 
CNTNAP2, for which rare deleterious 
mutations have been detected in individ-
uals with autism, mental retardation, and 
schizophrenia (Guilmatre et al., 2009).
Thus, mutations in genes involved with 
brain development may lead to a wide 
range of pleiotropic effects. Conversely, 
each neuropsychiatric outcome may be 
influenced by a variety of interacting fac-
tors, including dose and timing of gene 
expression, epistasis, RNA regulatory 
elements, epigenetic effects, and envi-
ronmental exposures. In principle, there 
are thousands of candidate genes for 
Figure 3. Genetic Heterogeneity of Inherited Hearing Loss
Thus far, 48 genes have been identified that harbor mutations responsible for inherited hearing loss. 
The genes encode proteins for a wide range of functions in the inner ear: hair bundle morphogenesis, 
including cytoskeleton, adhesion, scaffolding, and motor proteins (red); ion homeostasis, including con-
nexins, ion channels, and tight junctions (blue); extracellular matrix proteins (green), transcription factors 
(orange), and proteins whose function in hearing is not yet known (black). Every gene includes multiple 
deafness-associated mutations. GJB2, which encodes a gap junction protein, is the most frequently 
altered of these genes, although all mutations are individually rare. Each affected individual carries one 
dominant or two recessive mutations in only one gene.these illnesses, given that most human 
genes are expressed in brain. Many 
more genes responsible for neurologi-
cal and psychiatric disorders will be 
identified as sequencing technologies 
improve and the cost of screening indi-
vidual genomes falls. Characterization 
of the functional consequences of these 
mutations will help to elucidate both nor-
mal brain development and neurodevel-
opmental processes leading to disease 
(Geschwind, 2008).
Common Disease—Common 
Variants
The recognition that rare alleles are 
important contributors to common 
complex human diseases is a major 
paradigm shift in human genetics. In the 
past decade, until this shift, the search 
for disease-associated genes has been 
predicated almost entirely on the com-
mon disease-common variant model, 
which postulates that common illnesses 
stem from the additive or multiplicative 
effects of combinations of common vari-
ants (Risch and Merikangas, 1996). In 
this model, each “risk variant” is pos-
tulated to confer only a small degree of risk, with no one variant sufficient 
to cause the disorder. Disease onset 
is postulated as the result of the com-
bined effects of many such alleles. The 
model dates to Francis Galton (1872) and 
early population genetics theory (Fisher, 
1918; Wright, 1934; Falconer, 1965) and 
with recent technology could be tested 
directly.
For each common disease, “risk vari-
ants” have been identified by comparing 
allele frequencies at hundreds of thou-
sands of polymorphic sites (SNPs) in 
thousands of cases versus thousands of 
controls. To date, genome-wide associa-
tion studies (GWAS) have published hun-
dreds of common variants whose allele 
frequencies are statistically correlated 
with various illnesses and traits. How-
ever, the vast majority of such variants 
have no established biological relevance 
to disease or clinical utility for progno-
sis or treatment. For example, a recently 
published 12 year follow-up study of car-
diovascular disease (CVD) in more than 
19,000 women found that the 101 SNPs 
identified by GWAS as risk variants for 
CVD did not predict cardiovascular out-
comes (Paynter et al., 2010). More gen-Ceerally, it is now clear that common risk 
variants fail to explain the vast majority 
of genetic heritability for any human dis-
ease, either individually or collectively 
(Manolio et al., 2009).
Do common variants ever make 
a major contribution to disease? Of 
course. Sickle cell anemia and the thala-
ssemias are caused by multiple muta-
tions in hemoglobin genes that persist 
at polymorphic frequencies in malarial 
endemic regions worldwide (Patrinos et 
al., 2005). Autoimmune conditions, such 
as systemic lupus erythematosis, mul-
tiple sclerosis, type I diabetes, and rheu-
matoid arthritis, are strongly influenced 
by common polymorphic variation at the 
histocompatibility (MHC) loci (Fernando 
et al., 2008). Alzheimer’s disease is 
strongly influenced by an allele of APOE4 
that occurs at polymorphic frequen-
cies in most populations (Bird, 2005). 
Lactose intolerance (or lactase persis-
tence) is caused by the effect of any one 
of several different alleles in noncoding 
enhancers of the lactase promoter; dif-
ferent regulatory alleles are common 
in different populations (Tishkoff et al., 
2007). Pharmacogenomics holds imme-
diate promise for personalized medicine, 
for example by genotyping CYP2C9 and 
VKORC1 to improve the safety of warfa-
rin (Gurwitz and Motulsky, 2007).
These traits and the common alleles 
influencing them illustrate two important 
points. First, each common risk vari-
ant leads to a demonstrable functional 
difference in the protein it encodes or 
regulates. In contrast, the majority of vari-
ants detected by GWAS have no demon-
strated biological significance. Second, 
the persistence of these common alleles 
reflects evolutionary forces: deleterious 
alleles in hemoglobins were maintained 
by selection for heterozygotes driven by 
malaria (sickle cell anemia and the thalas-
semias); geographic-specific variation in 
immune response is protective against 
geographic-specific infection (autoim-
mune conditions); the illness has no effect 
on fitness because it appears well after 
reproductive life (Alzheimer’s disease); 
a medication introduces a new environ-
mental challenge not previously under 
evolutionary pressure (drug response).
The genetic architecture of a disorder, 
i.e., the number and frequency of sus-
ceptibility alleles, is shaped by evolution-ll 141, April 16, 2010 ©2010 Elsevier Inc. 213
ary factors, including the impact of the 
illness on selection (Pritchard and Cox, 
2002). In order to be maintained at poly-
morphic frequencies worldwide, com-
mon variants with even modest influence 
on disease must withstand selective 
pressure in every generation. Not sur-
prisingly, therefore, the common alleles 
with the best documented relationship 
to disease are associated with disorders 
that arise later in life, i.e., Alzheimer dis-
ease’s or age-related macular degenera-
tion. For illnesses that impact reproduc-
tive fitness, balancing positive selection 
is often demonstrable. Illness in these 
cases may arise from interaction between 
genetic and environmental factors, such 
that an otherwise adaptive mechanism 
or trait is deleterious in certain individu-
als. For example, adaptive inflammatory 
responses can cause autoimmune dis-
orders when turned against the host, or 
efficient storage of calories can lead to 
type II diabetes or to obesity in food-rich 
cultures.
Both common and rare alleles may 
lead to the same disease. For example, 
multiple rare mutations in any one of 
several genes (e.g., APP, PS1, PS2, and 
UBQLN1) lead to early-onset Alzheimer’s 
disease (Bird, 2005). Rare mutations in 
genes involved in immune response 
(e.g., DNASEI, TREX1) confer a very high 
risk for lupus (Moser et al., 2009). Each 
of these conditions is characterized by 
allele and locus heterogeneity. How-
ever, it should not be anticipated that all 
complex diseases will have substantial 
contributions from common risk vari-
ants. This is especially true for illnesses 
that reduce fertility, either biologically 
or through social selection against mar-
riage with individuals with severe dis-
eases. Alleles of significant effect must 
be enabled by evolutionary forces to 
persist at polymorphic frequencies.
Genome-wide Association Studies
It has become commonplace in the 
genetics community to aver that 
genome-wide association studies have 
led to the identification of hundreds of 
SNPs as “risk variants” for common 
diseases, while acknowledging that 
most of the heritability for these traits 
remains to be explained (Manolio et 
al., 2009). We agree with this conclu-
sion: that most of the inherited basis of 214 Cell 141, April 16, 2010 ©2010 Elsevier IFigure 4. Genetic Heterogeneity of Severe Mental Illness
Recent genomic analyses have revealed many individually rare, or even de novo, micro-deletions, micro-
duplications, and point mutations associated with schizophrenia (red), autism (blue), or both (black). The 
most frequently replicated genes and loci include DISC1, NRXN1 (neurexin), CNTNAP2, and SHANK3, as 
well as genomic hotspots at 1q21.1, 15q13.3, 16p11.2, and 22q11.2.ncommon traits remains to be explained 
(Goldstein, 2009). We further suggest 
that many GWAS findings stem from 
factors other than a true association 
with disease risk. The bases of our 
concern are both statistical and experi-
mental.
Cryptic Population Stratification
A major limitation complicating genome-
wide association studies is the poten-
tial for cryptic population stratification. 
Subtle differences in ancestry between 
cases and controls can produce spuri-
ous association solely due to sampling. 
GWAS study designs typically control 
for population structure in two ways: by 
taking into account differences among 
populations in average allele frequencies 
and by excluding individual subjects with 
extreme outlier genotypes (e.g., Price 
et al., 2006; Purcell et al., 2007). These 
approaches are appropriate and neces-
sary but not sufficient. Neither adjust-
ment addresses the problem posed by 
individual SNPs that are outliers with 
respect to variation in allele frequencies 
among healthy populations. A hypervari-
able SNP may be falsely identified as a 
risk variant if cases and controls are not 
perfectly matched. Stratifying cases and 
controls by self-reported ethnicity is not 
nearly sufficient to control for this prob-
lem (Serre et al., 2008).c.A recently published genome-wide 
association study of autism (Wang et al., 
2009) provides a particularly dramatic 
example of the perils of cryptic popu-
lation stratification. The SNP most sig-
nificantly associated with the illness was 
rs4307059 on chromosome 5p14.1. The 
ancestral T allele of rs4307059 was iden-
tified as the “risk variant,” with allele fre-
quencies in the discovery series of 0.65 
among cases and 0.61 among controls 
(odds ratio = 1.19, p = 3.4 × 10−8). All cases 
and controls were of European ancestry. 
The p value is compelling. However, the 
frequency of the proposed “risk variant” 
varies from 0.21 to 0.77 across Euro-
pean populations (Coop et al., 2009), a 
range 14-fold greater than the difference 
in allele frequencies between cases and 
controls. Even a subtle difference in the 
ancestries of cases and controls within 
Europe could explain the difference in 
allele frequencies that was attributed 
to the autism phenotype. An odds ratio 
of 3.0, or even of 2.0 depending on 
population allele frequencies, would be 
robust to such population stratification. 
However, odds ratios of the magnitude 
generally detected by GWAS (<1.5) can 
frequently be explained by cryptic popu-
lation stratification, regardless of the p 
value associated with them. The varia-
tion in allele frequencies at rs4307059 is 
particularly striking worldwide: in virtually 
all African populations, the frequency of 
the “risk variant” is 1.00. A subsequent 
analysis did not replicate the association 
between rs4307059 and autism (Weiss et 
al., 2009) and in fact found the opposite 
trend: the minor allele was more frequent 
among affected persons.
In large trans-continental studies of 
human populations, there is almost never 
perfect ancestral matching of cases and 
controls. To the extent that variants with 
greatest variability in frequency among 
control populations disproportion-
ately emerge as significant findings in 
genome-wide association studies, pop-
ulation stratification may explain appar-
ent disease associations. Replication 
studies, based on still larger samples, 
are generally suggested as the resolu-
tion of this problem. However, depend-
ing on sampling strategies for cases 
and controls in each geographic locale, 
larger samples may replicate, rather than 
resolve, imperfect matching.
Investigators devote a great deal of 
effort to the problem of population strati-
fication. Subjects who are deemed outli-
ers based on substructure analysis are 
generally removed from GWAS. However, 
hypervariable polymorphisms remain 
vulnerable to stratification even after this 
adjustment. Strategies to address this 
problem include using family designs 
to compare genotypes of cases to their 
healthy relatives and removing hyper-
variable SNPs from analyses.
Function: The Definition of “in” a 
Gene
A major limitation of genome-wide asso-
ciation studies is the lack of any func-
tional link between the vast majority of 
risk variants and the disorders they puta-
tively influence. It has become common 
practice to describe risk variants derived 
from GWAS as “in” a gene, suggest-
ing that the gene harboring the variant 
influences the disorder. But “in” in this 
context has a purely physical mean-
ing: that the risk variant lies somewhere 
in a genomic locus that also includes a 
gene. In the human genome, approxi-
mately 35% of base pairs lie in introns, 
and therefore approximately the same 
proportion of SNPs lie “in” genes. In this 
context, “in” is a tautology, not a proof of 
biological relevance. Very few published 
risk variants lie in coding regions, in UTRs, in promoters, or even in predicted 
intronic or intergenic regulatory regions. 
Far fewer have been shown to alter the 
function of any of these sequences.
How did genome-wide association 
studies come to be populated by risk 
variants with no known function? Stan-
dard genotyping platforms are designed 
to screen common SNPs, which were 
selected to be the most variable among 
individuals. As described above, evolu-
tionary forces have led to most common 
variation being neutral. Given that com-
mon variants are surveyed, it should not 
be surprising if most reported associa-
tions are neutral.
Search for Meaning in GWAS: 
Linkage Disequilibrium
Two approaches have been used to 
demonstrate the biological importance 
of risk variants detected in GWAS. One 
hypothesis is that a risk variant is not 
itself a critical functional variant, but 
is in linkage disequilibrium, in a subset 
of cases, with a rarer mutation of clear 
functional effect. The principle is that 
linkage disequilibrium (or LD) of risk 
variants with rare mutations of func-
tional effect leads to statistical asso-
ciations in genome-wide association 
studies. The hypothesis is reasonable 
if genetic heterogeneity of the disease 
is very low in the series of cases under 
study. That is, a significant associa-
tion in a GWAS may reflect a functional 
mutation by LD if the (unknown) func-
tional mutation is responsible for a 
substantial proportion of the illness in 
the cases surveyed.
For example, a GWAS of sickle cell 
anemia among African Americans 
yielded a meaningful association for an 
SNP near the beta hemoglobin gene 
HBB (Dickson et al., 2010) because most 
cases of sickle cell anemia among Afri-
can Americans are caused by the same 
mutation in HBB. Selection over the 
past several thousand years in favor of 
heterozygosity for the HBB-S mutation 
has maintained the allele at common 
frequency in West Africa and hence an 
elevated prevalence among Americans 
with West African ancestry. Similarly, a 
GWAS of inherited hearing loss among 
European American children yielded a 
meaningful association for an SNP near 
the gap junction protein GJB2 (Dickson 
et al., 2010) because the same mutation Cell in GJB2 is responsible for most cases of 
inherited hearing loss among European 
American children.
In both of these examples, in the 
population studied, the condition is not 
characterized by marked genetic het-
erogeneity. Had sickle cell anemia been 
investigated among affected individu-
als worldwide, the number of respon-
sible mutations would be far greater and 
hence no one allele at any SNP would be 
consistently associated with the disease. 
Similarly, had inherited hearing loss 
been investigated in a region where it is 
more common (e.g., in the Middle East), 
many different genes and an even larger 
number of causal mutations would be 
involved. Thus no one allele at any SNP 
would be consistently associated with 
the condition. In geographically isolated 
populations, localized disease homoge-
neity has led to successful applications 
of the GWAS approach (Kristiansson et 
al., 2008). The approach is far less likely 
to be successful in studies in heteroge-
neous populations of common diseases 
that involve multiple disease genes, 
each harboring multiple rare mutations, 
in LD with different alleles of neighbor-
ing SNPs.
Search for Meaning in GWAS: 
Distant Regulators
The second approach to demonstrating 
the biological importance of risk variants 
detected in GWAS is to assess whether 
a risk variant regulates a gene at con-
siderable genomic distance from the 
locale of the SNP. It is well established 
that mutations in noncoding sequence 
far removed from coding sequence can 
alter gene expression and lead to a 
severe phenotype. For example, disrup-
tion of an enhancer site more than 1 MB 
from the sonic hedgehog gene Shh leads 
to polydactyly in mouse (Lettice et al., 
2002). Multiple different mutations in the 
coding sequence of Shh in humans can 
cause the comparable polydactyly phe-
notype as well as other far more severe 
patterning aberrations (Quinlan et al., 
2008). Among risk variants detected by 
GWAS, an example that may prove par-
allel is SNP rs6983267, which has been 
identified in several studies as associ-
ated with colon cancer. rs6983267 lies in 
a gene desert, 335 kb from the oncogene 
MYC. Despite the considerable genomic 
distance, alternate alleles of rs6983267 141, April 16, 2010 ©2010 Elsevier Inc. 215
regulate expression of MYC by 1.5-fold 
(Tuupanen et al., 2009; Pomerantz et al., 
2009). However, there is no difference in 
MYC expression in colon tumors based 
on the rs6983267 genotype.
The general failure to confirm com-
mon risk variants is not due to a failure to 
carry out GWAS properly. The problem is 
underlying biology, not the operational-
ization of study design. The common dis-
ease—common variant model has been 
the primary focus of human genomics 
over the last decade. Numerous interna-
tional collaborative efforts representing 
hundreds of important human diseases 
and traits have been carried out with large 
well-characterized cohorts of cases and 
controls. If common alleles influenced 
common diseases, many would have 
been found by now. The issue is not how 
to develop still larger studies, or how to 
parse the data still further, but rather 
whether the common disease—common 
variant hypothesis has now been tested 
and found not to apply to most complex 
human diseases.
A Time to Sequence—With an 
Appreciation to Maynard Olson 
(Olson, 1995)
Genetic factors contributing to human 
disease are subject to the same evolu-
tionary forces that dictate the architec-
ture of the human genome. The overall 
magnitude of human genetic variation, 
the high rate of de novo mutation, the 
range of mutational mechanisms that 
disrupt gene function, and the complex-
ity of biological processes underlying 
pathophysiology all predict a substantial 
role for rare severe mutations in complex 
human disease. Furthermore, these fac-
tors explain why efforts to identify mean-
ingful common risk variants are vexed by 
irreproducible and biologically ambigu-
ous results.
Genome-wide screening for mutations 
remains the most effective and unbiased 
way to discover genes involved in com-
plex illnesses. Heretofore, the identifi-
cation of rare severe disease-causing 
variants was limited by the resolution of 
mutation detection strategies. The wide-
spread availability of next-generation 
sequencing technology renders this limi-
tation essentially moot. Designs based 
on genome-wide identification of all 
exonic variants, all variants in a defined 216 Cell 141, April 16, 2010 ©2010 Elsevier Igenomic region, or even all variants in a 
whole genome are replacing genome-
wide association approaches. How-
ever, although the power of sequenc-
ing is enormous, genetic heterogeneity 
remains a daunting challenge. With next-
generation sequencing technology, the 
issue is not finding potentially deleterious 
mutations but rather determining which 
of many potential deleterious mutations 
in an individual play a role in disease.
Two powerful strategies for identifying 
critical mutations are (1) tracing coinheri-
tance of potential disease alleles with the 
illness in severely affected families, and 
(2) identifying different rare functional 
mutations in the same gene in unrelated 
affected individuals. Experience with 
well-characterized disease genes indi-
cates that the first mutations discovered 
are generally those with severe effects, 
and that subsequent characterization of 
the gene’s mutational spectrum reveals 
additional point mutations and small 
frameshifts with severe effect, as well as 
hypomorphic alleles (e.g., Cohen et al., 
2004, 2006), regulatory mutations, and 
genomically cryptic mutation sites (e.g., 
Walsh and King, 2007; Dror and Avra-
ham, 2009).
New sequencing technologies provide 
conceptual and practical advantages 
over current approaches (Olson, 1995). 
Given genetic heterogeneity of complex 
traits, large numbers of affected individ-
uals and families are necessary to iden-
tify different disease-causing variants. 
With complete exome or full genome 
sequencing of each case, the concept 
of replication shifts. As described in this 
Essay, a powerful method of replication 
in genetics is the identification of differ-
ent biologically relevant mutations in the 
same gene. This important concept now 
expands to include the identification of 
functional mutations in genes acting in 
related biological pathways. The muta-
tional spectrum of each gene can be 
established using existing large cohorts. 
Any one gene may be responsible for only 
a small fraction of cases. The occurrence 
of multiple functional mutations among 
unrelated cases provides both biological 
evidence and epidemiological support for 
the causal role of the gene or pathway.
Next-generation sequencing provides 
its own challenges. Whole-genome 
sequencing strategies detect hundreds nc.of thousands of rare variants per indi-
vidual (McKernan et al., 2009). Biological 
relevance must be established before 
a mutation can be causally linked to 
a disorder. The critical question is not 
whether cases as a group have more rare 
events than controls; but rather which 
mutation(s) disrupting a gene is respon-
sible for the illness in the affected per-
son harboring the variant. Variable pen-
etrance, epistasis, epigenetic changes, 
and gene-environment interactions will 
complicate these efforts. It will be fun to 
sort out.
The ultimate goal of gene discovery 
in complex disease is to identify and 
characterize biological pathways and 
processes critical to the disorder. Key 
pathways may be disrupted via many dif-
ferent causes—genetic, epigenetic, and 
environmental. Even if the illness in every 
affected individual arises from a differ-
ent specific cause, each will nonetheless 
share disruption of related key biological 
processes. Defining the ways in which 
biological networks for common disease 
are impacted by mutation will contrib-
ute substantially to the understanding 
of their pathology and provide important 
targets for intervention.
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